Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CHKA | P35790 | 1/20 | 0.45 |
| ▸ | PTGIR | P43119 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.44 |
| ▸ | LSS | P48449 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1991840 | 0.81 | SIGMAR1 (0.52) | COMTSIGMAR1CYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL19285228 | 0.75 | SIGMAR1 (0.85) | SIGMAR1SMN1; SMN2CHKAPTGIRALDH1A1 | |
| SCHEMBL1043952 | 0.75 | SIGMAR1 (0.85) | SIGMAR1SMN1; SMN2CHKAPTGIRALDH1A1 | |
| SCHEMBL20804352 | 0.75 | SIGMAR1 (0.85) | SIGMAR1SMN1; SMN2CHKAPTGIRALDH1A1 | |
| SCHEMBL1777855 | 0.74 | SIGMAR1 (0.50) | COMTSIGMAR1SMN1; SMN2CHKAPTGIR | |
| SCHEMBL2760180 | 0.73 | NAMPT (0.33) | COMTSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL11394352 | 0.71 | SIGMAR1 (0.72) | SIGMAR1SMN1; SMN2CHKAPTGIRALDH1A1 | |
| SCHEMBL18894740 | 0.71 | COMT (1.00) | COMT | |
| SCHEMBL1043090 | 0.71 | SIGMAR1 (0.77) | SIGMAR1SMN1; SMN2CHKAPTGIRPOLB | |
| SCHEMBL1045386 | 0.71 | SIGMAR1 (0.77) | SIGMAR1SMN1; SMN2CHKAPTGIRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127792-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-04-24 | — | — | US | disclosed |
| US-12186324-B2 | Imidazopiperazine inhibitors of transcription activating proteins | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-01-07 | — | — | US | disclosed |
| CN-112165944-B | Imidazopiperazine inhibitors of transcriptional activator proteins | 德州大学系统董事会 | 2024-04-09 | — | — | CN | disclosed |
| US-20230008047-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-01-12 | — | — | US | disclosed |
| US-20230008047-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-01-12 | — | — | US | disclosed |
| US-11058688-B2 | Imidazopiperazine inhibitors of transcription activating proteins | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-07-13 | — | — | US | disclosed |
| US-11058688-B2 | Imidazopiperazine inhibitors of transcription activating proteins | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-07-13 | — | — | US | disclosed |
| CN-112165944-A | Imidazopiperazine inhibitors of transcriptional activator proteins | 德州大学系统董事会 | 2021-01-01 | — | — | CN | disclosed |
| US-20190298729-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-10-03 | — | — | US | disclosed |
| US-20190298729-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-10-03 | — | — | US | disclosed |
| US-8309571-B2 | Heterobicyclic compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-13 | — | — | US | disclosed |
| US-20110190292-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-04 | — | — | US | disclosed |
| US-20110190292-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-04 | — | — | US | disclosed |
| US-20110190292-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-04 | — | — | US | disclosed |
| US-7943617-B2 | Especially p38 MAP kinase alpha and beta; 2,4-difluorophenyl(3-(2-(trifluoromethyl)phenyl)-5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-yl)methanone | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-17 | — | — | US | disclosed |
| US-7943617-B2 | Especially p38 MAP kinase alpha and beta; 2,4-difluorophenyl(3-(2-(trifluoromethyl)phenyl)-5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-yl)methanone | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-17 | — | — | US | disclosed |
| US-7943617-B2 | Especially p38 MAP kinase alpha and beta; 2,4-difluorophenyl(3-(2-(trifluoromethyl)phenyl)-5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-yl)methanone | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-17 | — | — | US | disclosed |
| US-20080275052-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-06 | — | — | US | disclosed |
| US-20080275052-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-06 | — | — | US | disclosed |
| US-20080275052-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275052-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS KINASE INHIBITORS | MAP2K2, MAP2K6, MAP2K1 | COMT 2918/4885SIGMAR1 1042/4885SMN1; SMN2 3169/4885 |
| US-11058688-B2 | Imidazopiperazine inhibitors of transcription activating proteins | EP300, CREBBP, RBBP7 | COMT 4383/4885SIGMAR1 4158/4885SMN1; SMN2 3825/4885 |
| US-20230008047-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | EP300, CREBBP, RBBP7 | COMT 4383/4885SIGMAR1 4158/4885SMN1; SMN2 3825/4885 |
| US-20110190292-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS KINASE INHIBITORS | MAP2K2, MAP2K6, MAP2K1 | COMT 2918/4885SIGMAR1 1042/4885SMN1; SMN2 3169/4885 |
| US-20250127792-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | EP300, CREBBP, RBBP7 | COMT 4383/4885SIGMAR1 4158/4885SMN1; SMN2 3825/4885 |
| US-12186324-B2 | Imidazopiperazine inhibitors of transcription activating proteins | EP300, CREBBP, RBBP7 | COMT 4383/4885SIGMAR1 4158/4885SMN1; SMN2 3825/4885 |
| US-20190298729-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | EP300, CREBBP, RBBP7 | COMT 4383/4885SIGMAR1 4158/4885SMN1; SMN2 3825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.